Sierra Oncology is a late stage drug development company focused on developing momelotinib, a potent, selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor, for myelofibrosis. Momelotinib's differentiated therapeutic profile encompasses constitutional symptom improvements, anemia benefits, and spleen control. Sierra has launched the MOMENTUM, a randomized double-blind Phase 3 clinical trial designed to enroll 180 myelofibrosis patients who are symptomatic and anemic, and who have been treated previously with a JAK inhibitor.
Location: Canada, British Columbia, Vancouver
Member count: 51-200
Total raised: $34M
Founded date: 2003
Investors 6
| Date | Name | Website |
| - | RA Capital... | racap.com |
| - | OrbiMed | orbimed.co... |
| - | Adams Stre... | adamsstree... |
| - | Abingworth... | abingworth... |
| - | Vivo Capit... | vivocapita... |
| - | Longitude ... | longitudec... |
Funding Rounds 1
| Date | Series | Amount | Investors | Deal News |
| 10.08.2021 | - | $34M | - | orbimed.co... |
Mentions in press and media 11
| Date | Title | Description | Category | Author | Source |
| 13.04.2022 | Will Solan... | This is the web version of Ter... | - | - | fortune.co... |
| 25.01.2022 | Sierra suc... | A drug abandoned by Gilead Sci... | - | - | medcitynew... |
| 09.08.2021 | Sierra Onc... | - | - | - | orbimed.co... |
| 09.08.2021 | Sierra Onc... | Sierra Oncology, Inc. (NASDAQ:... | - | - | marketscre... |
| 07.11.2019 | Sierra Onc... | - | - | - | vivocapita... |
| 18.08.2019 | FDA approv... | Prior to Inrebic’s approval, t... | - | - | medcitynew... |
| 15.09.2018 | 40 AND UND... | This story is available exclus... | - | - | businessin... |
| 15.08.2018 | Artios rai... | Artios plans to use the money ... | - | - | medcitynew... |
| - | Artios rai... | A company developing cancer th... | - | - | medcitynew... |
| - | Sierra suc... | A drug abandoned by Gilead Sci... | - | - | medcitynew... |
Show more